Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine

• Published in: The Journal of infectious diseases Vol. 216; no. 11; pp. 1343 - 1351
• Main Authors: Grupping, Katrijn, Campora, Laura, Douha, Martine, Heineman, Thomas C., Klein, Nicola P., Lal, Himal, Peterson, James, Vastiau, Ilse, Oostvogels, Lidia
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 12.12.2017
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - adverse effects; Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Antibodies, Viral - blood; CD4-Positive T-Lymphocytes - immunology; Drug-Related Side Effects and Adverse Reactions - epidemiology; Editor's Choice; Female; Herpes Zoster - immunology; Herpes Zoster - prevention & control; Herpes Zoster Vaccine - administration & dosage; Herpes Zoster Vaccine - adverse effects; Herpes Zoster Vaccine - immunology; Herpesvirus 3, Human - immunology; Humans; Immunity, Cellular - immunology; Immunity, Humoral - immunology; Immunization, Secondary; Immunogenicity, Vaccine; Major and Brief Reports; Male; Vaccination - methods; Vaccines, Attenuated - immunology; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - adverse effects; Vaccines, Subunit - immunology; Viral Envelope Proteins - immunology; VIRUSES; live attenuated zoster vaccine Zostavax; herpes zoster; revaccination; HZ/su adjuvanted herpes zoster subunit vaccine; immune response
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/jix482

The adjuvanted herpes zoster subunit vaccine candidate induces strong humoral and cellular immune responses irrespective of prior vaccination with the live attenuated zoster vaccine (ZVL), and may be an attractive option to revaccinate prior ZVL recipients. Abstract Background Protection against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3–7 years. Revaccination may renew protection. We assessed whether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune responses in previous ZVL recipients and ZVL-naive individuals (HZ-NonVac). Methods In an open-label, multicenter study, adults ≥65 years of age, vaccinated with ZVL ≥5 years previously (HZ-PreVac), were matched to ZVL-naive adults (HZ-NonVac). Participants received 2 doses of HZ/su 2 months apart. The primary objective of noninferiority of the humoral immune response 1 month post–dose 2 was considered demonstrated if the upper limit of the 95% confidence interval (CI) of the adjusted anti–glycoprotein E geometric mean concentration (GMC) ratio of HZ-NonVac over HZ-PreVac was <1.5. HZ/su cellular immunogenicity, reactogenicity, and safety were also assessed. Results In 430 participants, humoral immune response to HZ/su was noninferior in HZ-PreVac compared with HZ-NonVac (adjusted GMC ratio, 1.04 [95% CI, .92–1.17]). Cellular immunogenicity, reactogenicity, and safety appeared to be comparable between groups. HZ/su was well-tolerated, with no safety concerns raised within 1 month post–dose 2. Conclusions HZ/su induces a strong immune response irrespective of prior vaccination with ZVL, and may be an attractive option to revaccinate prior ZVL recipients. Clinical Trials Registration NCT02581410.